



Haematology Cancer Clinical Guidelines

Haematology Expert Advisory Group (EAG)
on behalf of Northern Cancer Alliance

Title:	Haematology Cancer Clinical Guidelines
Authors:	Haematology EAG
Circulation List:	Haematology EAG Members
Contact Details:	Mrs C McNeill, Senior Administrator, Cancer Alliance
Telephone:	01138252976

Version History:

Date:	10.04.18	Version:	V17- section16	Review Date:	November 2019
--------------	----------	-----------------	----------------	---------------------	---------------

Document Control

Version	Date	Summary	Review Date
V17			

Date Agreed: Haematology EAG members agreed the Guidelines on:
Emailed to group on 12.04.18, for formal endorsement at the next meeting

Review Date: November 2019

CONTENTS

SECTION 1 NEHODS- Northern England Haemato- Diagnostic Service

SECTION 2 Guidelines for Cytogenetic analysis in Haematological Malignancies

SECTION 3 North of England Cancer Network Guidelines and Indications for PETCT

SECTION 4 Guidelines for management of Acute Myeloid Leukaemia (AML)

SECTION 5 Guidelines for Management of Myelodysplastic Syndromes

SECTION 6 Guidelines for Management of Acute Lymphoblastic Leukaemia

SECTION 7 Guidelines for the Management of Chronic Myeloid Leukaemia

SECTION 8

Guidelines for Management of Myeloproliferative Disorders

Polycythaemia Vera (PRV)

Myelofibrosis (MF)

SECTION 9

Guidelines for Management of Chronic Lymphocytic Leukaemia (CLL) and Lymphoproliferative Disorders

Hairy Cell Leukaemia

T-Prolymphocytic Leukaemia

Waldenstrom Macroglobulinaemia

SECTION 10

Guidelines for the Management of Low-grade Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

SECTION 11 Guidelines for the Management of High Grade B Cell Non-Hodgkin Lymphoma (NHL)

SECTION 12 Guidelines for the Management of Classical Hodgkin Lymphoma

SECTION 13 Guidelines for the Management of Mature T-Cell and NK-Cell Neoplasms

SECTION 14 Guidelines for Management of Plasma Cell Myeloma

SECTION 15 Indications for Haemopoietic Stem Cell Transplantation

SECTION 16 Clinical Guideline for the prophylaxis and treatment of tumour lysis syndrome in patients receiving treatment for haematological malignancies

SECTION 17 Blood Transfusion Guidelines

SECTION Appendix

Appendix 1 – Teenage and Young Adult Pathway for initial Management

Appendix 2 – Pathway for follow up on completion of First line treatment

Appendix 3- TYA Designated Hospitals

Appendix 4 – NHS Specialised Services Pathway

Appendix 5 – Local Referral Pathways and Levels of Care

Appendix 6 - Pathways

Appendix 7 – Inter-provider transfers

- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma

SECTION 16

Clinical Guideline for the prophylaxis and treatment of tumour lysis syndrome in patients receiving treatment for haematological malignancies

Tumour lysis syndrome is an oncological emergency caused by massive tumour cell death causing release of potassium, phosphate and nucleic acids into the blood stream. It can occur spontaneously but is most commonly associated with initiation of chemotherapy. Sequelae include acute kidney injury, cardiac arrhythmias, seizures, neurological complications and sudden death.

Tumour lysis definition

Element	Value	Change from baseline
<i>Laboratory Tumour lysis syndrome</i>		
Uric acid	≥476 micromol/L	25% increase
Potassium	≥6.0 mmol/L	25% increase
Phosphorus	≥1.45 mmol/L	25% increase
Calcium	≤1.75 mmol/L	25% decrease
<i>Clinical Tumour lysis syndrome – laboratory tumour lysis and ≥1 of the following</i>		
Creatinine	>1.5 ULN	
Cardiac arrhythmia		
Sudden death		
Seizure		

Risk Stratification

Risk stratification should be carried out prior to initiation of first cycle of chemotherapy and used to guide the prescription of appropriate prophylactic therapy. The risk can be estimated from the disease type and presence of additional risk factors.

Risk Group	Disease Type	Additional Risk Factors <i>(move up one risk group for each additional risk factor present)</i>
High	Burkitt's lymphoma/leukaemia	Bulky disease (>10cm) Renal Impairment Renal involvement or urinary tract obstruction by tumour Raised LDH (>2x ULN) Baseline uric acid, phosphate or potassium > ULN
	AML and ALL with WCC $\geq 100 \times 10^9/l$	
Intermediate	AML and ALL with WCC < $100 \times 10^9/l$	
	Intermediate and high grade NHL with LDH $\geq 2 \times$ ULN	
	CML accelerated phase/blast crisis	
	CLL with targeted and/or biological therapy	
Low	Myeloma	
	Other CLL	
	Hodgkin's Lymphoma	
	Low grade NHL	
	CML – chronic phase	
	Myeloproliferative disorders	

Modified from Cario MS et al, BJH 2010, 149, 578-586

Prevention of tumour lysis syndrome

Prophylaxis should be prescribed based on estimated risk of tumour lysis. Prophylaxis is usually only required for the first cycle of cytotoxic chemotherapy as tumour burden will be significantly reduced at the time of subsequent treatment.

Risk Group	Prophylaxis
Low	Hydration (aim for 3L day)* +/- Allopurinol 300mg od**
Intermediate	Hydration (aim for 3L day) and Allopurinol 300mg od.**
High	Hydration (aim for up to 2L/m ²) for up to 7 days following chemotherapy and Rasburicase 3mg iv. ***

*Hydration should start 24 hours before chemotherapy starts and continue for 7 days

**Allopurinol should be started no more than 12-24 hours pre chemotherapy and continued for up to 7 days. The dose of allopurinol should be reduced to 100mg od in patients with CrCl < 20ml/min. Patients with an allergy to allopurinol should be treated with hydration and monitored closely for evidence of tumour lysis.

***Rasburicase should be given immediately prior to starting chemotherapy. Repeat dose only if indicated by biochemical markers. Rasburicase should not be given to patients with G6PD. Allopurinol may partially antagonise the effect of rasburicase and should not be co-administered.

Patients at high risk of tumour lysis syndrome will usually need to be admitted for in patient monitoring following chemotherapy. IV fluids may be required if patients are unable to maintain an adequate fluid intake and fluid balance should be monitored closely. U&Es, calcium, phosphate and uric acid should be monitored twice daily for the first 72 hours (more frequently if there is evidence to suggest laboratory tumour lysis is developing). Samples for uric acid must be sent to the laboratory on ice.

Treatment of clinical tumour lysis syndrome

Increase hydration to 3L/m² with close attention to fluid balance aiming for a urine output of >100ml/m²/h.

Treat hyperuricaemia with Rasburicase 0.2mg/kg repeated daily as required.

If Hyperphosphataemia and hyperkalaemia are present then the patient should be referred to ICU for consideration of renal support therapy. Standard measures to control hyperkalaemia should be used as a bridge to renal support but the effects will usually be short duration.

Asymptomatic hypocalcaemia should not be treated as calcium administration can precipitate calcium phosphate precipitation in the kidneys. If the calcium is ≤ 1.75 mmol/l or drops by $\geq 25\%$ from baseline then the patient should have cardiac monitoring. Symptomatic hypocalcaemia should be treated with calcium gluconate according at standard doses.